Jai Prakash

Jai Prakash is a Professor (adjunct) and Head of Targeted Therapeutics at the Technical Medical Centre, University of Twente (Netherlands). His current research focus is to design novel targeted (nano)therapeutics against fibrotic diseases and fibrotic cancers.

He is a pharmaceutical and entrepreneurial scientist with a strong background in developing novel targeted therapeutics against fibrosis and tumor stroma. His research is highly multi-/inter-disciplinary integrating peptide technology, nanomedicine, biology of cancer and fibrosis, as well as bioengineering fields. He obtained PhD (cum laude) in 2006 from University of Groningen (Netherlands) in the field of drug targeting to treat renal fibrosis under the supervision of Prof. Klaas Poelstra. Thereafter, he worked as a Vice President – Preclinical Research at BiOrion Technologies with a joint position at the University of Groningen. During this period, he developed several products, which are being translated by BiOrion. Besides that, he co-supervised PhD students on the topics related to cell-specific targeting to liver fibrosis. In 2011, he joined the group of Prof. Arne Ostman atKarolinska Institutet in Stockholm (Sweden) as Forskarassistent (Assistant Professor) in the Department of Oncology-Pathology. In 2012, he was appointed as a Tenure track Assistant Professor at University of Twente to set up his new research line. He was then promoted to Associate Professor in 2015 and then to Adjunct Professor in 2018. In 2019, he also worked at the School of Engineering and Applied Sciences in the lab of Prof. Samir Mitragotri at Harvard University for his sabbaticals as a visiting professor.

He has published 77 peer-reviewed publications including high-impact papers in Science Advances, Advanced Materials, etc. He is also (co)-inventor on 5 international patents. He is an Associate Editor for Frontiers in Oncology and has been main theme editor for Advanced Drug Delivery Reviews. He is also the Managing Director of ScarTec Therapeutics BV., which he founded in 2016 and aims to develop novel therapeutic technologies against skin scars and cancers with high stroma.